Imaxen 400 mg (Tablet)
Unit Price: ৳ 350.00 (1 x 14: ৳ 4,900.00)
Strip Price: ৳ 4,900.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Imatinib mesylate |
| Company | Everest pharmaceuticals ltd |
| Also available as |
Title
- Imaxen
- Imatinib Tablet
Categories
- Pharmaceutical
- Cancer Treatment
- Medication
Description
- Imaxen is a small molecule protein-tyrosine kinase inhibitor used to treat various types of leukemia and tumors.
- It inhibits Bcr-Abl tyrosine kinase, as well as receptors such as Kit, DDR1, DDR2, CSF-1R, PDGFR-alpha, and PDGFR-beta.
Dimensions
N/A
Color Options
N/A
Functions
- Inhibition of protein-tyrosine kinases
- Treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML)
Materials
N/A
Technical Specifications
- Absorption: Cmax achieved within 2-4 hours post-dose
- Bioavailability: Mean absolute bioavailability is 98%
- Metabolism: Primarily metabolized by CYP3A4, minor role by other CYP enzymes
- Excretion: Elimination is predominately in the feces, with approximately 81% of the dose being eliminated within 7 days
Design Elements
N/A
Usability Features
- Dosage & Administration:
- Adults with Ph+ CML CP: 400 mg/day
- Pediatrics with Ph+ CML CP: 340 mg/m2/day
- Imatinib should be taken with a meal and a large glass of water
- Interaction:
- Concomitant administration of Imaxen and strong CYP3A4 inhibitors may result in a significant imatinib exposure increase
- Storage Conditions: Store below 30°C, in a cool and dry place, away from light and out of the reach of children
Additional Features
- Indications:
- Treatment of Philadelphia chromosome positive chronic myeloid leukemia in various phases
- Treatment of acute lymphoblastic leukemia
- Treatment of myelodysplastic/myeloproliferative diseases associated with PDGFR gene rearrangements
- Treatment of aggressive systemic mastocytosis
- Treatment of hypereosinophilic syndrome and/or chronic eosinophilic leukemia
- Treatment of dermatofibrosarcoma protuberans
- Treatment of unresectable and/or metastatic gastrointestinal stromal tumors
- Side Effects:
- Fluid Retention and Edema
- Hematologic Toxicity
- Congestive Heart Failure and Left Ventricular Dysfunction
- Hepatotoxicity
- Hemorrhage
- Gastrointestinal Disorders
- Hypothyroidism
- Tumor Lysis Syndrome
- Renal Toxicity
- Pregnancy & Lactation:
- Women of childbearing potential must use effective contraception during treatment and for at least 15 days after stopping treatment with Imatinib
- Imatinib should not be used during pregnancy unless clearly necessary
- Breastfeeding should be avoided during treatment and for at least 15 days after stopping treatment with Imatinib
- Precautions & Warnings:
- Severe fluid retention and edema
- Cytopenias, particularly anemia, neutropenia, and thrombocytopenia
- Severe hepatotoxicity
- Grade 3/4 hemorrhage
- Cardiogenic shock/left ventricular dysfunction
- Bullous dermatologic reactions
- Fetal harm can occur when administered to a pregnant woman
- Growth retardation in children and pre-adolescents
- Tumor Lysis Syndrome
- Reports of motor vehicle accidents in patients receiving Imatinib
- Overdose Effects: Symptomatic treatment should be given in the event of overdose
Therapeutic Class
Targeted Cancer Therapy, Tyrosine Kinase Inhibitor